Next Article in Journal
Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?
Next Article in Special Issue
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
Previous Article in Journal
Estimation of Serial Interval and Reproduction Number to Quantify the Transmissibility of SARS-CoV-2 Omicron Variant in South Korea
Previous Article in Special Issue
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 14
Issue 3
10.3390/v14030532
Review Report
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Communication
Peer-Review Record

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection

Viruses 2022, 14(3), 532; https://doi.org/10.3390/v14030532
by Alexandra Tauzin 1,2, Gabrielle Gendron-Lepage 1, Manon Nayrac 1,2, Sai Priya Anand 1,3, Catherine Bourassa 1, Halima Medjahed 1, Guillaume Goyette 1, Mathieu Dubé 1, Renée Bazin 4, Daniel E. Kaufmann 1,5 and Andrés Finzi 1,2,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Viruses 2022, 14(3), 532; https://doi.org/10.3390/v14030532
Submission received: 11 February 2022 / Revised: 28 February 2022 / Accepted: 2 March 2022 / Published: 4 March 2022
(This article belongs to the Special Issue Basic Sciences for the Conquest of COVID-19)

Round 1

Reviewer 1 Report

Congratulation is a well written and interesting article.

Have you diagnosed different variants of COVID-19?

Could variants have a different immunological behaviour?

Author Response

Please see attached rebuttal.

Author Response File: Author Response.pdf

Reviewer 2 Report

It is a very interesting article to read. It provided timely and valuable data to the COVID-19 management. Authors developed the simple and straightforward method to help monitor the antibody response. Few questions need authors to clarify:

  1. Have the author verified the quality and purity of SARS-CoV-2 S RBD protein?
  2. In the results section, 3.1, authors listed the process and criteria for the sample collection. I think it is better to put these in the Material and Methods section. 
  3. How many replicates of ELISA analysis did the authors do?
  4. In Figure 2, in the left panel of B, why the y-axis presented as RBD avidity index, not the RLU normalized results? Can you please clarity why?
  5. In the discussion, authors mentioned that "Our data suggest that an extended interval (16 weeks) between the first and...with the antigen". Please clarify how did you give 16 weeks conclusion? In your results you only compared at 3 and 12 weeks PSO and post vaccination. 

Author Response

Please see attached rebuttal.

Author Response File: Author Response.pdf

Reviewer 3 Report

This manuscript describes the progressive increase in anti-RBD IgG avidity after SARS-CoV-2 infection or vaccination. This is a well written manuscript with robust statistical analysis to support the case. I have two minor concerns which authors should address to improve the merit of the manuscript.

  • Authors should provide gating strategy for the flow cytometry experiment.
  • The details of cohort should be provided for comprehensive analysis of data. For example, if there was any comorbidities in the cohort.

Author Response

Please see attached rebuttal.

Author Response File: Author Response.pdf

Back to TopTop